Avicanna (TSX:AVCN,OTCQX:AVCNF) signed a new deal with Cannvalate for the supply of medical cannabis products under its brand Rho Phyto in Australia.

As quoted in the press release:

Avicanna has also agreed to supply Cannvalate with a line of advanced cannabinoid phyto-therapeutic products that Avicanna has chosen to offer on a white-labelled basis (the “White-Label Products“, collectively with the Rho Products and APIs, the “Products“).

“After significant due diligence into the Australian market and its operators we are pleased to be able to introduce Cannvalate as our partners in the region. Our two companies are aligned on a strictly medical approach backed by sustainable processes, data driven R&D and clinical development which will be to the benefit of the Australian patients and medical community at large,” stated Aras Azadian, Chief Executive Officer of Avicanna.

Click here to read the full press release.